Moreover, we observed that AML patients with BRAF mutations exhibited an extremely poor prognosis compared to those without BRAF mutations, regardless of whether they had de novo AML or secondary AML, the specific subtypes of BRAF mutation, or the different chemotherapy regimens. Here, BRAF is linked to acute myeloid leukemia.